Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of SPD503 and Psychostimulants in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with a primary diagnosis of ADHD~* Subject on a stable dose of a psychostimulant approved for the treatment of ADHD for at least 1 month, with sub-optimal control in the Investigator's opinion~* Male or non-pregnant female subject who agrees to comply with any applicable contraceptive requirements~Exclusion Criteria:~* Subject has current uncontrolled comorbid psychiatric diagnosis (except ODD and mild anxiety) with significant symptoms~* History of seizure during the last 2 years~* Subject has any specific cardiac condition or family history of significant cardiac condition~* Subject is pregnant or lactating

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Methylphenidate + SPD503 (Type: EXPERIMENTAL): None
- Amphetamine + SPD503 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).